Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RYTM Rhythm Pharmaceuticals Inc.

Market Closed 08-14 16:00:00 EDT

115.48

-0.54

-0.47%

盘后115.48

+0.000.00%

19:34 EDT

High117.33	Low113.66	Vol334.88K
Open115.22	D1 Closing116.02	Amplitude3.17%
Mkt Cap7.95B	Tradable Cap6.32B	Total Shares68.85M
T/O38.75M	T/O Rate0.61%	Tradable Shares54.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RYTM","market":"US","secType":"STK","nameCN":"Rhythm Pharmaceuticals Inc.","latestPrice":115.48,"timestamp":1786737600000,"preClose":116.02,"halted":0,"volume":334876,"hourTrading":{"tag":"盘后","latestPrice":115.48,"preClose":115.48,"latestTime":"19:34 EDT","volume":5355,"amount":618398.01,"timestamp":1786750449695,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004654369936217825,"floatShares":54766316,"shares":68852082,"eps":-3.117162,"marketStatus":"Market Closed","change":-0.54,"latestTime":"08-14 16:00:00 EDT","open":115.22,"high":117.3337,"low":113.66,"amount":38746812.845456,"amplitude":0.031664,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.117162,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1507176000000,"exchange":"NASDAQ","adjPreClose":116.02,"preHourTrading":{"tag":"盘前","latestPrice":115.48,"preClose":116.02,"latestTime":"09:29 EDT","volume":1861,"amount":215447.16977,"timestamp":1786714199999,"change":-0.54,"changeRate":-0.004654,"amplitude":0.060248},"postHourTrading":{"tag":"盘后","latestPrice":115.48,"preClose":115.48,"latestTime":"19:34 EDT","volume":5355,"amount":618398.01,"timestamp":1786750449695,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4819394321635108,"impliedVol":0.3894,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/RYTM","defaultTab":"news","newsList":[{"id":"2659577122","title":"Rhythm Pharma EVP, Head of International Yann Mazabraud Sells USD 6.61 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659577122","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659577122?lang=en_us&edition=fundamental","pubTime":"2026-08-15 07:02","pubTimestamp":1786748565,"startTime":"0","endTime":"0","summary":"Rhythm Pharma EVP, Head of International Yann Mazabraud sells USD 6.61 million in common sharesRhythm Pharmaceuticals EVP, Head of International Yann Mazabraud cut his stake to 55,655 shares in transactions dated Aug. 12.Disposed of 56,?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3ZSG63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rhythm Pharma EVP, Head of International Yann Mazabraud Sells USD 6.61 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","MEDI","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658315990","title":"UK MHRA Expands Rhythm’s Imcivree Authorization to Treat Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2658315990","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658315990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449829,"startTime":"0","endTime":"0","summary":"UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesityUK MHRA expanded IMCIVREE (setmelanotide) authorization for acquired hypothalamic obesity in patients aged 4 and o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL5z8LQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","RYTM","NDAQ","LU2095319765.USD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","MEDI","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658861990","title":"Rhythm Pharmaceuticals: to Work Closely with UK's Nhs to Finalize Guidance for Coverage of Imcivree for Acquired Ho","url":"https://stock-news.laohu8.com/highlight/detail?id=2658861990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658861990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480NY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDI","BK4588","BK4585","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658084997","title":"Rhythm Pharmaceuticals Announces Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658084997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658084997?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449608,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RYTM","MEDI","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640758","title":"Rhythm Pharmaceuticals Price Target Raised to $146.00/Share from $145.00 by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640758?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:53","pubTimestamp":1786121580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MEDI","BK4139","RYTM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668501","title":"How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668501","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668501?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:37","pubTimestamp":1786045066,"startTime":"0","endTime":"0","summary":"In August 2026, Rhythm Pharmaceuticals reported second-quarter 2026 results showing revenue of US$71.26 million versus US$48.50 million a year earlier, alongside a net loss of US$49.30 million and slightly improved loss per share. \nThe company also released early Phase 2 data for its weekly MC4R agonist RM-718 in acquired hypothalamic obesity, showing double-digit BMI reductions with fewer pigmentation issues, highlighting progress beyond its first-generation IMCIVREE franchise. \nNow we’ll...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-q2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-q2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MEDI","BK4588","RYTM","BK4166","BK4139","RM","ISBC","BK4211","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657352510","title":"Rhythm Pharmaceuticals is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657352510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657352510?lang=en_us&edition=fundamental","pubTime":"2026-08-05 23:21","pubTimestamp":1785943260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RYTM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MEDI","BK4588","RYTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657733542","title":"RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657733542","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657733542?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:48","pubTimestamp":1785934099,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) has an average rating of buy and mean price target of $141.47, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","RYTM","BK4139","MEDI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657549701","title":"Immuneering Expects Cash Runway to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657549701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657549701?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:40","pubTimestamp":1785930027,"startTime":"0","endTime":"0","summary":"Immuneering expects cash runway to fund operations into 2029OverviewUS oncology drug developer's Q2 net loss beat analyst expectations, loss per share met consensusCompany ended Q2 with $182.7 mln in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0861579265.USD","BBH","SG9999001440.SGD","LU0432979614.USD","LU2242652126.USD","RYTM","BK4533","AMGN","LU0203345920.USD","LU0942090050.USD","LU2089984988.USD","BK4566","IBBQ","LU2087621335.USD","LU0823416689.USD","LU0320765992.SGD","LU0114720955.EUR","LU1571399168.USD","IE00B4R5TH58.HKD","LU1674673428.USD","TMED","IE00BZ1G4Q59.USD","LU1066053197.SGD","IE0002270589.USD","LU1023059063.AUD","LU1057294990.SGD","BK4581","BK4550","SG9999015952.SGD","SG9999015986.USD","IMRX","BK4539","MEDI","MCK","GILD","IBB","LU1814569148.SGD","PJP","PBE","LU0109394709.USD","BIB","BMED","IE00B19Z3581.USD","LU2324357040.USD","LU0965509101.SGD","LU1934455863.HKD","LU0868494617.USD","IE00B2B36J28.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510151","title":"Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510151?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:50","pubTimestamp":1785923416,"startTime":"0","endTime":"0","summary":"Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $160 from $155 and keeps an Outperform rating on the shares. Imcivree s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-160-from-155-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-pharmaceuticals-price-target-raised-to-160-from-155-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","BK4588","RYTM","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763518","title":"Sweden's Xspray Posts Narrow Q2 Pretax Loss as Costs Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763518?lang=en_us&edition=fundamental","pubTime":"2026-08-05 14:16","pubTimestamp":1785910587,"startTime":"0","endTime":"0","summary":"Sweden's Xspray posts narrow Q2 pretax loss as costs fallOverviewSweden pharmaceutical developer reported no Q2 sales as products remain in clinical stagePretax loss for Q2 narrowed yr/yr, reflecting ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N44207U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","MEDI","RYTM","KROS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657404561","title":"Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657404561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657404561?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:18","pubTimestamp":1785874711,"startTime":"0","endTime":"0","summary":"Ultragenyx Q2 revenue rises 28% to record high, net loss narrowsOverviewUS biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company historyNet loss for Q2 narrowed yr/yr, with lo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N441167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4585","HRMY","MEDI","BK4139","PSCH","BK4007","RARE","RYTM","BK4588","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657611015","title":"Travere Therapeutics Q2 Product Sales Rise on Filspari Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611015","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657611015?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:15","pubTimestamp":1785874544,"startTime":"0","endTime":"0","summary":"Travere Therapeutics Q2 product sales rise on FILSPARI demandOverviewU.S. biopharma's Q2 net product sales rose 70% yr/yr, driven by FILSPARI growthCompany posted a Q2 net loss after a $40 mln inducem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4585","MEDI","BK4139","RYTM","IBRX","TVTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561681","title":"Precigen Posts Quarterly Profit as Papzimeos Sales Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561681","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657561681?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:15","pubTimestamp":1785874515,"startTime":"0","endTime":"0","summary":"Precigen posts quarterly profit as PAPZIMEOS sales surgeOverviewUS biopharma firm's Q2 revenue surged on PAPZIMEOS sales, driving quarterly profitabilityCompany reversed prior-year loss, reporting net","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RYTM","LU0289739343.SGD","BK4567","BK4533","LU0289961442.SGD","LU0069063385.USD","BK4149","LU2463526074.USD","LU0203347892.USD","MEDI","BK4585","LU0154245756.USD","LU0511384066.AUD","PGEN","BK4139","LU0124676726.USD","CMI","IE000M9KFDE8.USD","LU0057025933.USD","MADE","LU0472753341.HKD","BK4588","LU0154245673.USD","LU0203345920.USD","LU0689626769.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561508","title":"Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657561508?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:14","pubTimestamp":1785874443,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026OverviewUS biotech firm's Q2 net loss and pretax loss were lower than analyst expectationsQ2 results included a $40 mln ga","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4588","MEDI","SYRE","DSGN","PVLA","BK4585","LFSC","RYTM","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657056901","title":"Rigel Pharmaceuticals Q2 Revenue Rises on Strong Product Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657056901","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657056901?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:11","pubTimestamp":1785874311,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals Q2 revenue rises on strong product demandOverviewBiotechnology firm's Q2 revenue rose, with net product sales up 14% yr/yrQ2 net income fell from prior year due to absence of $40","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","RIGL","HRMY","MEDI","BK4139","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569703","title":"Arrowhead Pharmaceuticals Q3 Revenue Jumps on Redemplo Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569703","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569703?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:10","pubTimestamp":1785874254,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals Q3 revenue jumps on REDEMPLO growthOverviewRNAi therapeutics developer's fiscal Q3 revenue rose sharply, beating analyst expectationsCompany posted a wider net loss as operat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4007","BK4588","BK4585","BK4139","ARWR","MEDI","INDV","RYTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657356963","title":"Rhythm Pharma Executives to Speak at Canaccord Genuity Growth Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2657356963","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657356963?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873889,"startTime":"0","endTime":"0","summary":"Rhythm Pharma executives to speak at Canaccord Genuity Growth Conference fireside chatRhythm Pharmaceuticals will join three investor-conference fireside chats in August and September 2026.CFO Hunter ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL3qx2df:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","SG9999014005.SGD","RYTM","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","MEDI","IE00B3QW5Z07.USD","BK4585","BK4139","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657456873","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657456873","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657456873?lang=en_us&edition=fundamental","pubTime":"2026-08-05 01:20","pubTimestamp":1785864028,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), Rhythm Pharmaceuticals (RY...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-275?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-275?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","BK4505","BK4588","RYTM","BK4556","BK4139","LU1861558580.USD","BK4611","LU1861559042.SGD","BK4535","BEAM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656988551","title":"Rhythm Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656988551","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656988551?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:31","pubTimestamp":1785850305,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryRhythm Pharmaceuticals IncRYTM.OQreported a quarterly adjusted loss of 73 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RYTM","MEDI","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rhythmtx.com","stockEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":0.0528},{"period":"3month","weight":0.2757},{"period":"6month","weight":0.1775},{"period":"1year","weight":0.1969},{"period":"ytd","weight":0.0788}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051908},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.048958},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.056668},{"month":4,"riseRate":0.555556,"avgChangeRate":0.013671},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045608},{"month":6,"riseRate":0.555556,"avgChangeRate":0.069919},{"month":7,"riseRate":0.444444,"avgChangeRate":0.238637},{"month":8,"riseRate":0.777778,"avgChangeRate":0.230982},{"month":9,"riseRate":0.375,"avgChangeRate":-0.040591},{"month":10,"riseRate":0.375,"avgChangeRate":-0.015139},{"month":11,"riseRate":0.777778,"avgChangeRate":0.136999},{"month":12,"riseRate":0.555556,"avgChangeRate":0.041318}],"exchange":"NASDAQ","name":"Rhythm Pharmaceuticals Inc.","nameEN":"Rhythm Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Rhythm Pharmaceuticals Inc.,RYTM,Rhythm Pharmaceuticals Inc.股票,Rhythm Pharmaceuticals Inc.股票老虎,Rhythm Pharmaceuticals Inc.股票老虎国际,Rhythm Pharmaceuticals Inc.行情,Rhythm Pharmaceuticals Inc.股票行情,Rhythm Pharmaceuticals Inc.股价,Rhythm Pharmaceuticals Inc.股市,Rhythm Pharmaceuticals Inc.股票价格,Rhythm Pharmaceuticals Inc.股票交易,Rhythm Pharmaceuticals Inc.股票购买,Rhythm Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rhythm Pharmaceuticals Inc.(RYTM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Rhythm Pharmaceuticals Inc.(RYTM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}